Skip to main content Accessibility help
×
×
Home

Second-generation antipsychotics and metabolic side-effects: Canadian population-based study

  • Lauren Hirsch (a1), Scott B. Patten (a2), Lauren Bresee (a3), Nathalie Jette (a2) and Tamara Pringsheim (a4)...

Abstract

Background

Use of second-generation antipsychotics (SGA) has increased in recent years; however, their use and effect on metabolic outcomes has been poorly characterised in population-level studies.

Aims

This study aimed to determine the associations between SGA use and metabolic indicators in a general population.

Method

We used data from the Canadian Health Measures Survey, a cross-sectional survey of Canadian households. Participants were Canadians aged 3–79 years, living in one of the ten provinces. Several metabolic indicators were examined, including weight, body mass index, waist circumference, hypertension, diabetes and two definitions of metabolic syndrome.

Results

The proportion of Canadians taking an SGA tripled over the study period. SGA use was significantly associated with hypertension (odds ratio 1.94, 95% CI 1.07–3.55) and abdominal obesity in adults, as defined by the National Cholesterol Education Program–Adult Treatment Panel III (odds ratio 2.62, 95% CI 1.45–4.71).

Conclusions

Evidence of metabolic dysfunction with SGAs is seen in the Canadian population, along with a rapid increase in prevalence of use since 2007.

Declaration of interest

None.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Second-generation antipsychotics and metabolic side-effects: Canadian population-based study
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Second-generation antipsychotics and metabolic side-effects: Canadian population-based study
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Second-generation antipsychotics and metabolic side-effects: Canadian population-based study
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

Corresponding author

Correspondence: Tamara Pringsheim, Mathison Centre for Mental Health Research and Education, 3280 Hospital Drive NW, Calgary, Alberta T2N 4Z6, Canada. Email: tmprings@ucalgary.ca

References

Hide All
1Pringsheim, T, Gardner, D. Dispensed prescriptions for quetiapine and other second generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open 2014; 2(4): E22532.
2Pringsheim, T, Lam, D, Patten, SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents, 2005-2009. J Child Adolesc Psychopharmacol 2011; 21(6): 18.
3Divac, N, Prostran, M, Jakovcevski, I, Cerovac, N. Second generation antipsychotics and extrapyramidal adverse events. Biomed Res Int 2014; 2014: 656370.
4Chaplain, S, Taylor, M. Drug points: second generation antipsychotics. Prescriber 2014; 14(21): 1221.
5McEvoy, J, Meyer, J, Goff, D, Nasrallah, HA, Davis, S, Sullivan, L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80(1): 1932.
6Kurzthaler, I, Fleischhacker, WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001; 62(suppl 7): 32–7.
7Hagg, S, Lindblom, Y, Mjorndal, T, Adolfsoon, R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21: 93–8.
8Brown, S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502–8.
9Mortensen, P, Juel, K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183–9.
10Harris, E, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 1153.
11Laursen, T, Munk-Olsen, T, Vestergaard, M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25(2): 83–8.
12Statistics Canada. Canadian Health Measures Survey 2016–2017. Statistics Canada, 2017 (http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5071).
13Tremblay, M, Wolfson, M, Gorber, S. Canadian Health Measures Survey: rationale, background and overview. Health Rep 2007; 18(suppl): 620.
14Bryan, S, St-Denis, M, Wojtas, D. Canadian Health Measures Survey: clinic operations and logistics. Health Rep 2007; 82(suppl): 5270.
15NCEP–ATP III. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). Final Report. Circulation 2002; 106: 3143–421.
16Alberti, K, Zimmet, P, Shaw, J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006; 23: 469–80.
17Alessi-Severini, S, Biscontri, R, Collins, D, Kozyrskyj, A, Sareen, J, Enns, M. Utilization and costs of antipsychotic agents: a Canadian population based study 1996-2006. Psychiatr Serv 2008; 59(5): 547–53.
18Alessi-Severini, S, Biscontri, R, Collins, D, Sareen, J, Enns, M. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 2012; 57(1): 52–8.
19Dewa, C, Remington, G, Herrmann, N, Fearnley, J, Goering, P. How much are atypical antipsychoitc agents being used, and do they reach the populations who need them? A Canadian experience. Clin Ther 2002; 24(9): 1466–76.
20Murphy, A, Gardner, DM, Cooke, C, Kisely, S, Hughes, J, Kutcher, S. Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry 2013; 13(198): 113.
21Duncan, D, Cooke, L, Symonds, C, Gardner, DM, Pringsheim, T. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open 2016; 6: 17.
22Patten, S, Williams, J, Lavorato, D, Fiest, K, Bulloch, A, Wang, J. The prevalence of major depression is not changing. Can J Psychiatry 2015; 60(1): 31–4.
23Schaffer, A, Cairney, J, Cheung, A, Veldhuizen, S, Levitt, A. Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry 2006; 51(1): 916.
24McDonald, K, Bulloch, A, Duffy, A, Bresee, L, Williams, J, Lavorato, D, et al. Prevalence of bipolar I and II disorder in Canada. Can J Psychiatry 2015; 60(3): 151–6.
25Herbeck, D, West, J, Ruditis, I, Duffy, F, Fitek, D, Bell, C, et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv 2004; 55(6): 677–84.
26Opolka, J, Rascati, K, Brown, C, Gibson, P. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 2004; 55(2): 151–6.
27Connolly, A, Taylor, D. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry 2008; 193(2): 161–2.
28Public Health Agency of Canada and Canadian Institute for Health Information. Obesity in Canada. Public Health Agency of Canada and Canadian Institute for Health Information, 2011 (https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/hp-ps/hl-mvs/oic-oac/assets/pdf/oic-oac-eng.pdf).
29Aronne, L, Segal, K. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003; 64(suppl 8): 22–9.
30Printz, D, Clark, J, Stricks, L, Malaspina, D. Weight gain in bipolar disorder: causes and treatments. Primary Psychiatry 2003; 10(11): 2936.
31Haupt, D, Rosenblatt, L, Kim, E, Baker, R, Whitehead, R, Newcomer, J. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166(3): 345–53.
32Morrato, E, Druss, B, Hartung, D, Valuck, R, Allen, R, Campagna, E, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67(1): 1724.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Open
  • ISSN: -
  • EISSN: 2056-4724
  • URL: /core/journals/bjpsych-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Second-generation antipsychotics and metabolic side-effects: Canadian population-based study

  • Lauren Hirsch (a1), Scott B. Patten (a2), Lauren Bresee (a3), Nathalie Jette (a2) and Tamara Pringsheim (a4)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *